Skip to main content Skip to main content
Go to homepage

Ferimoxytol vs. Iron Sucrose

Ferimoxytol vs. Iron Sucrose in Pediatric Anemia Patients


To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric chronic kidney disease (CKD) subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA.

For complete study information please visit

Who May Qualify?:
  1. Male or female 2 years to <18 years of age at time of consent
  2. Has IDA defined as: a) hemoglobin <12.0 g/dL and b) with either transferrin saturation (TSAT) <40% or ferritin <100 ng/mL; or considered to be at risk of development of IDA, i.e., TSAT<20% with falling hemoglobin during the preceding 2 months and a history of hemoglobin <12 g/dL
  3. Has Chronic Kidney Disease defined as one of the following:
    • on chronic hemodialysis;
    • receiving chronic peritoneal dialysis;
    • estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2;
    • has evidence of structural and/or functional abnormalities e.g., persistent albuminuria, abnormal urine sediment, electrolyte and other abnormalities due to tubular disorders for > 3 months.
  4. For patients other than hemodialysis dependent CKD patients, documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate
  5. All subjects (female and male) of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to Day 1 Dosing and agree to remain on birth control until completion of the study
Who Does Not Qualify:
  1. Known hypersensitivity reaction to any component of ferumoxytol and iron sucrose
  2. History of allergy to intravenous (IV) iron
  3. History of multiple drug allergies (>2)
  4. Low systolic blood pressure (Age 1-9 years <70 + [age in years x 2] mmHg, Age 10-17 years <90 mmHg)
  5. Hemoglobin ≤7.0 g/dL
  6. Serum ferritin level >600 ng/mL
  7. Children younger than 2 or over 17 years
Study Status:
Study Sponsor:

AMAG Pharmaceuticals

Full IRB Study Title:
A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease Protocol No: AMAG-FER-CKD-354
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email
Lead Investigator
Rupesh Raina, MD, FACP, FAAP

Pediatric Nephrologist
Pediatric NephrologyPediatric Hypertension ClinicKidney Stone Clinic

Summit Mall Play Area
Answer Key:
Click to expand
There are 10 nurses in the picture.

And we have many more pediatric primary care providers in Northeast Ohio. You can meet some of them here.
Summit Mall Play Area
Answer Key:
Click to expand
The five differences are:
– Phone color
– Coat pocket
– Stethoscope earpiece color
– Stethoscope bell dot
– Clipboard paper color

Need help finding a doctor, choosing a location or getting a general question about Akron Children's answered? Call us or fill out the form and we'll help in any way we can.
Summit Mall Play Area
Answer Key:
Click to expand
The two matching doctors are 9 and 14.

With virtual visits, you can see our pediatric experts from the comfort of home or wherever you are.
Summit Mall Play Area
Answer Key:
Click to expand
The correct path:
The Correct Path
We offer many ways to get pediatric care all over Northeast Ohio. Use this page to find the right kind of care and the most convenient location for you.